|Day Low/High||68.12 / 69.98|
|52 Wk Low/High||60.32 / 79.61|
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses from the ZUMA-1 trial of Yescarta ® (axicabtagene ciloleucel) in adult patients with relapsed or refractory large B-cell lymphoma.
Kite, a Gilead Company (Nasdaq: GILD), today announced results from the completed Phase 1 of the ZUMA-3 study evaluating KTE-X19, an investigational CD19 chimeric antigen receptor T (CAR T) cell therapy.
Kite, a Gilead Company (Nasdaq: GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta ® (axicabtagene...
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in...
Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Johanna Mercier will join the company as Chief Commercial Officer, and will become a member of the company's senior leadership team.
Shares of Gilead Sciences fall after Goldman Sachs downgrades the stock to sell from neutral.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will participate in a fireside chat at the Jefferies 2019 Global Healthcare Conference in New York on Wednesday, June 5 at 11:30 a.
Kite, a Gilead Company (Nasdaq: GILD), today announced that new data from its cell therapy programs will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from May 31 - June 4, 2019.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it will donate Truvada for PrEP ® (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) to the U.
Gilead Sciences, Inc. (Nasdaq: GILD) and Goldfinch Bio, Inc.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.
Gilead Sciences' adjusted earnings in the first quarter beat analysts' expectations.
Revenue is stabilizing with new treatment lines, and this stock may be a soon be a buy.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter ended March 31, 2019.
U.S. stock futures are higher, rebounding from declines in the previous session after a policy statement from the Federal Reserve suggested U.S. interest rates likely will remain unchanged for the better part of the year; Qualcomm tumbles after forecasting weaker-than-expected third-quarter revenue; Square issues a weak earnings forecast for the second quarter; Beyond Meat's IPO is priced at $25 a share.
Gilead Sciences revenue expected to rise 4.1% to $5.3 billion.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Robin Washington, Executive Vice President (EVP) and Chief Financial Officer (CFO), plans to retire from her role, effective March 1, 2020.
Friday felt a lot like Tuesday -- in that it didn’t change any of the big indicators -- but we should still pay close attention to the Citigroup Panic/Euphoria Index, which is now kissing the underside of Euphoria.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis...
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes.
If you want a good read on the economy, look at the details of CSX's latest earnings report.
Jim Cramer weighs in on Nvidia, Advanced Micro Devices, Constellation Brands, Bausch Health, Arista Networks, Gilead Sciences and more.
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Gilead Sciences Inc. (Nasdaq: GILD) and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH).
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.